Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Rhabdomyosarcoma 8Wilms Tumor 6Sarcoma 6Malignant mesenchymal tumor 4Rhabdomyosarcoma, Embryonal 2Kidney Neoplasms 2Hydatidiform Mole 2Stage I Mixed Cell Type Kidney Wilms Tumor 1Sarcoma, Ewing 1Rhabdomyosarcoma, Alveolar 1Pleuropulmonary blastoma 1Gestational Trophoblastic Disease 1Fibrosarcoma 1Choriocarcinoma 1Carcinoma, Renal Cell 1Beckwith-Wiedemann Syndrome 1

Interventions

lorvotuzumab mertansine 1Watchful Waiting 1Vincristine 1Topotecan 1Specimen Handling 1Razoxane 1Polymerase Chain Reaction 1Observation 1Magnetic Resonance Spectroscopy 1Ifosfamide 1High-Energy Shock Waves 1Gene Rearrangement 1Gene Expression Profiling 1Doxorubicin 1Dexrazoxane 1Dactinomycin 1Cytogenetic Analysis 1Cyclophosphamide 1Amplified Fragment Length Polymorphism Analysis 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Pleuropulmonary blastoma × Dactinomycin × Clear all
NCT06647953 2026-05-05

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

Children's Oncology Group

Phase 3 Recruiting
110 enrolled

Pleuropulmonary blastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡